Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences
© Guerquin-Kern et al; licensee BioMed Central Ltd. 2004
Received: 21 November 2003
Accepted: 06 April 2004
Published: 06 April 2004
Analytical imaging by secondary ion mass spectrometry (SIMS) provides images representative of the distribution of a specific ion within a sample surface. For the last fifteen years, concerted collaborative research to design a new ion microprobe with high technical standards in both mass and lateral resolution as well as in sensitivity has led to the CAMECA NanoSims 50, recently introduced onto the market. This instrument has decisive capabilities, which allow biological applications of SIMS microscopy at a level previously inaccessible. Its potential is illustrated here by the demonstration of the specific affinity of a melanoma marker for melanin. This finding is of great importance for the diagnosis and/or treatment of malignant melanoma, a tumour whose worldwide incidence is continuously growing.
The characteristics of the instrument are briefly described and an example of application is given. This example deals with the intracellular localization of an iodo-benzamide used as a diagnostic tool for the scintigraphic detection of melanic cells (e.g. metastasis of malignant melanoma). B16 melanoma cells were injected intravenously to C57BL6/J1/co mice. Multiple B16 melanoma colonies developed in the lungs of treated animals within three weeks. Iodobenzamide was injected intravenously in tumour bearing mice six hours before sacrifice. Small pieces of lung were prepared for SIMS analysis.
Mouse lung B16 melanoma colonies were observed with high lateral resolution. Cyanide ions gave "histological" images of the cell, representative of the distribution of C and N containing molecules (e.g. proteins, nucleic acids, melanin, etc.) while phosphorus ions are mainly produced by nucleic acids. Iodine was detected only in melanosomes, confirming the specific affinity of the drug for melanin. No drug was found in normal lung tissue.
This study demonstrates the potential of SIMS microscopy, which allows the study of ultra structural distribution of a drug within a cell. On the basis of our observations, drug internalization via membrane sigma receptors can be excluded.
Progress in cellular imaging allows access not only to qualitative aspects of living structures but also to quantitative data. These data are of considerable interest, especially in pharmaco-toxicology, to understand the mechanisms by which drugs interact with physiological processes. Such analytical methods have, for a long time, been restricted to fluorescence measurements, either directly or after immuno-conjugation, thus severely limiting the development of such applications. In the last few decades, new techniques have appeared, including X-ray fluorescence, electron energy loss spectroscopy, and secondary ion mass spectroscopy (SIMS).
Initially introduced 40 years ago , SIMS imaging has found its main uses in microanalysis of mineral samples, e.g. in geology, metallurgy, and semiconductor sciences. Application of this "ion microscopy" to life sciences was attempted by Pierre Galle more than 30 years ago . However, the complex nature of biological samples and the poor performance of the first instruments limited its use to various "histological" studies, mainly in nuclear medicine and radionuclide toxicology.
high lateral resolution (≤50 nm with caesium primary ions and ≤150 nm with oxygen primary ions),
capability to measure up to 5 masses (ions) in parallel, coming from the same micro volume (ensuring perfect isotopic ratio from the same small volume or perfect image superimposition)
very good transmission, e.g. high sensitivity, even at high mass resolution (60% at M/ΔM = 5000).
The main advantage of this technology is the ability to make direct observation of the distribution of any element (and all isotopes) occurring at the surface of a sample, without any specific labelling with a fluorescent or radioactive probe.
In the present paper, we describe an example of application of this new ion microprobe to a problem in cancer pharmacology, the targeting of melanin for the diagnosis and/or the treatment of malignant melanoma.
The worldwide incidence of malignant melanoma is continuously increasing [8, 9] and it is now evident that diagnosis at an early stage is the most effective way to limit mortality. The most common tool to determine the extent of the disease is whole body scintigraphic exploration and, for this purpose, two classes of compounds are currently under investigation, 18F-fluorodeoxyglugose (18FdG), a non-specific tumoral tracer , and 125I-iodobenzamides (125I-BZA), a series of specific imaging agents for melanoma [11–16]. These latter molecules can also be used as internal radio therapeutic agents after labelling with the β-emitter 131I. Whilst the affinity of these iodobenzamides for melanoma tissue has been the subject of numerous studies, their tissue and cell distribution as well as their uptake mechanism remain controversial. A recent SIMS microscopy study of tissues that were either neoplastic or from normal pigmented skin, of C57Bl6/J1 mice inocculated with malignant murine B16 melanocytes has shown the intracytoplasmic localization of the drug in both types of cell. However, lateral resolution of the instrument was too low to identify any characteristic intra-cellular structure such as melanosomes, and so the results were not fully conclusive . The results presented here demonstrate unambiguously the specific affinity of the studied iodobenzamide for melanin pigments present within melanosomes.
B16 murine melanoma cells were cultivated in minimal essential medium (MEM) supplemented with 10% foetal calf serum (FCS) and standard antibiotics. For transplantation, cells were trypsinized and washed with buffered saline (PBS) containing 5% FCS. Then, cells were resuspended in PBS (1.5 × 10-6 cells/mL) and 0.2 mL of the suspension was injected intravenously to C57BL6/J1/co mice (Iffa Credo, France). Multiple B16 melanoma colonies developed in the lungs within three weeks. All animal use and handling was carried out following Institutional guidelines for animal welfare.
N-2-Diethylaminoethyl-4-iodobenzamide (127I-BZA) was injected intravenously in tumour bearing mice (0.9 mg/0.2 mL/mouse; 2.6 μmole) 6 hours before sacrifice. Lungs were removed and small pieces of tissue were fixed by slam freezing. Samples were dehydrated by lyophilization at -110°C before embedding in spurr® resin at low temperature. Serial sections of 0.4 μm were deposited on stainless steel disks for SIMS analysis or on glass slides for light microscopy.
SIMS observations were carried out on a Nanosims 50® micro beam analyzer (CAMECA, Courbevoie, France) using a Cs+ primary source (15 KeV). The probe was 80 nm in diameter, with an intensity of 1.5 pA. Distribution of negative ions: CN- (m = 27), P- (m = 31), and I- (m = 127) was recorded as a matrix of 256 × 256 image points.
Mass resolution (M/ΔM) was above 6000 and mass calibration was achieved using standard references. Lateral resolution was in the range 80–100 nm.
CN- ions correspond to nitrogen distribution, mainly from proteins and melanin, while phosphorus ions are essentially concentrated in the nucleus and are mostly emitted by nucleic acids. However, as expected, phosphorus is also apparent everywhere in the cell, whilst iodide ions only arise from BZA or/and its metabolites.
CN- distribution gives an image very similar to that obtained using light microscopy. We can observe some small grains (150–250 nm in diameter) as well as a cluster of such grains (Figs. 3A and 3D) with a very high signal intensity. These hyper signal areas are totally free of phosphorus signal (Figs. 3B and 3E), as expected for melanin, which is a polymeric structure containing no phosphorus. A perfect correlation is found between these structures and the iodine signal (Figs. 3C and 3F), thus indicating a specific colocalization of the drug with melanin. The cluster, which can be considered as a melanosome, and most melanin grains, are intracytoplasmic and no iodine signal can be observed at the cytoplasmic membrane locus. Therefore, our results invalidate, at least for N-2-diethylaminoethyl-4-iodobenzamide, the hypothesis of John and colleagues implicating a specific binding of benzamides to membrane sigma receptors [18, 19]. The same observations are true for figure 4, however, here the melanin grains are rare. Interestingly, in the CN- image (Fig. 4A), the central cell of the picture does not show any structured nucleus but rather a "patchwork" of high signal areas, which appear as very intense signals in the phosphorus image (Fig. 4B). This is consistent with a metaphasic cell in which the chromatin is already condensed into chromosomes. Normal lung tissue, shown in figure 5, did not elicit any significant iodine signal, thus indicating the high specificity of the drug for the melanin of pigmented cells.
Iodobenzamide has a high affinity for melanin and, when labelled with 125I, this molecule appears as a highly specific tool for the diagnosis of micro metastasis from pigmented malignant melanoma. Its use as an internal radionuclide therapeutic agent bearing the β-emitter 131I is currently under investigation. However, the therapeutic protocol should be established with great care, since BZA can also bind to normal pigmented cells, i.e. in the retina or in the skin, which can be destroyed as along with the targeted malignant cells.
This study demonstrates the high potential of SIMS microscopy, which now allows the study of ultra structural distribution of a drug within a cell. The high lateral resolution, as well as the high sensitivity, make possible the observation of organelles as small as melanosomes. This new technology merits further applications to the life sciences as a major advance to an "old".
The NanoSims 50 was purchased with financial support from INSERM, the Research division of the Curie Institute, the "Ile de France" district, the EDF radioprotection agency and ARC (contract n° 7401). All these institutions are gratefully acknowledged. Thanks to Alvin Wald and Jason Martin for editorial assistance.
- Castaing R, Slodzian G: Microanalyse par émission ionique secondaire. J Microsc 1962, 1: 395–410.Google Scholar
- Galle P: Sur une nouvelle méthode d'analyse cellulaire utilisant le phénomène d'émission ionique secondaire. Ann Phys Biol Med 1970, 42: 83–94.Google Scholar
- Morrison GH, Gay I, Chandra S: Ion microscopy in biology. Scanning Microsc Suppl 1994, 8: 359–70.Google Scholar
- Pacholski ML, Winograd N: Imaging with mass spectrometry. Chem Rev 1999, 99: 2977–3005. 10.1021/cr980137wView ArticleGoogle Scholar
- Todd PJ, Schaaff TG, Chaurand P, Caprioli RM: Organic ion imaging of biological tissue with secondary ion mass spectrometry and matrix-assisted laser desorption/ionization. J Mass Spectrom 2001, 36: 355–69. 10.1002/jms.153View ArticleGoogle Scholar
- Slodzian G, Daigne B, Girard F, Boust F, Hillion F: Scanning secondary ion analytical microscopy with parallel detection. Biol Cell 1992, 74: 43–50.View ArticleGoogle Scholar
- Hillion F, Daigne B, Girard F, Slodzian G, Schuhmacher M: A new high performance SIMS instrument: The Cameca "Nanosims 50". Secondary Ion Mass Spectrometry SIMS IX 1993, 254–257.Google Scholar
- Weinstock MA: Epidemiology of melanoma. Cancer Treat Res 1993, 65: 29–56.View ArticleGoogle Scholar
- Garbe C, Blum A: Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001, 14: 280–90. 10.1159/000056358View ArticleGoogle Scholar
- Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ: Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002, 89: 389–96. 10.1046/j.0007-1323.2002.02059.xView ArticleGoogle Scholar
- Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, Parry DF, Bonafous JF, Boire JY, Desplanches GG: Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991, 32: 1573–80.Google Scholar
- John CS, Saga T, Kinuya S, Le N, Jeong JM, Paik CH, Reba RC, Varma VM, McAfee JG: An improved synthesis of [125I]N-(diethylaminoethyl)-4-iodobenzamide: a potential ligand for imaging malignant melanoma. Nucl Med Biol 1993, 20: 75–9. 10.1016/0969-8051(93)90138-KView ArticleGoogle Scholar
- Labarre P, Papon J, Moreau MF, Moins N, Veyre A, Madelmont JC: Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multi-wire proportional counting. Eur J Nucl Med 1999, 26: 494–8. 10.1007/s002590050416View ArticleGoogle Scholar
- Moins N, Papon J, Seguin H, Gardette D, Moreau MF, Labarre P, Bayle M, Michelot J, Gramain JC, Madelmont JC, Veyre A: Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 2001, 28: 799–808. 10.1016/S0969-8051(01)00242-6View ArticleGoogle Scholar
- Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, Madelmont JC: Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 2002, 12: 115–21. 10.1097/00008390-200204000-00003View ArticleGoogle Scholar
- Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, Mestas D, Noirault E, Chossat F, Berthommier E, Papon J, Bayle M, Souteyrand P, Madelmont JC, Veyre A: 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging 2002, 29: 1478–84. 10.1007/s00259-002-0971-6View ArticleGoogle Scholar
- Chehade F, De Labriolle-Vaylet C, Michelot J, Moins N, Moreau MF, Hindie E, Papon J, Escaig F, Galle P, Veyre A: Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: a study by secondary ion mass spectroscopy. Cell Mol Biol (Noisy-le-grand) 2001, 47: 529–34.Google Scholar
- John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, Paik CH, Reba RC, Neumann RD, Varma VM: A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 1993, 34: 2169–75.Google Scholar
- Caveliers V, Everaert H, Lahoutte T, Dierickx LO, John CS, Bossuyt A: Labelled sigma receptor ligands: can their role in neurology and oncology be extended? Eur J Nucl Med 2001, 28: 133–5. 10.1007/s002590000368View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.